Patents by Inventor Michael Lehnerer

Michael Lehnerer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Processing of recombinant human G-CSF precursor
    Patent number: 8436142
    Abstract: A G-CSF precursor comprising a signal peptide and a G-CSF peptide, wherein the signal peptide has the sequence of the human wild-type signal peptide of the human G-CSF/b molecule with at least one of the following mutations: deletion of Glu29, insertion of Glu26, substitution Lys11Leu, substitution His21Phe, and substitution Gln28Leu.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: May 7, 2013
    Assignee: Octapharma AG
    Inventors: Carola Schröder, Elisabeth Casademunt, Peter Söhlemann, Michael Lehnerer
  • PROCESSING OF RECOMBINANT HUMAN G-CSF
    Publication number: 20110294989
    Abstract: A G-CSF precursor comprising a signal peptide and a G-CSF peptide, wherein the signal peptide has the sequence of the human wild-type signal peptide of the human G-CSF/b molecule with at least one of the following mutations: deletion of Glu29, insertion of Glu26, substitution Lys11Leu, substitution His21Phe, and substitution Glu28Leu.
    Type: Application
    Filed: October 2, 2009
    Publication date: December 1, 2011
    Applicant: OCTOPHARMA BIOPHARMACEUTICALS GMBH
    Inventors: Carola Schröder, Elisabeth Casademunt, Peter Söhlemann, Michael Lehnerer
  • Recombinant blood clotting factors
    Patent number: 7572619
    Abstract: The present invention relates to an improved method for the production of recombinant human blood clotting factors, in particular of factor VIII and factor IX. An immortalized human cell line can be used to stably express viral transcription activator proteins and carrying a vector having a promoter functionally linked to a DNA sequence coding for a blood coagulating factor, provided that said promoter is not a viral promoter which is stimulated by said viral transcription activator proteins. The invention further relates to an immortalized human cell line carrying said vector, factor VIII muteins particularly suitable for the above production method; pharmaceutical compositions comprising such factor VIII muteins, and the use of such factor VIII muteins for preparing a medicament for treating hemophilia.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: August 11, 2009
    Assignee: Octagene GmbH
    Inventors: Charlotte Hauser, Andrea Hörster, Carola Schröder, Michael Lehnerer
  • Production of recombinant blood clotting factors in human cell lines
    Publication number: 20040023333
    Abstract: The present invention relates to an improved method for the production of recombinant human blood clotting factors, in particular of factor VIII and factor IX, utilizing an immortalized human cell line stably expressing viral transcription activator proteins and carrying a vector having a promoter functionally linked to a DNA sequence coding for a blood coagulating factor, provided that said promoter is not a viral promoter which is stimulated by said viral transcription activator proteins; an immortalized human cell line carrying said vector, factor VIII muteins particularly suitable for the above production method; pharmaceutical compositions comprising such factor VIII muteins and the use of such factor VIII muteins for preparing a medicament for treating hemophilia.
    Type: Application
    Filed: July 8, 2003
    Publication date: February 5, 2004
    Inventors: Charlotte Hauser, Andrea Horster, Carola Schroder, Michael Lehnerer